Labiotech.eu – View full story
This author has not written his bio yet.
But we are proud to say that ginealach contributed 55 entries already.
Entries by ginealach
FDANews – View full story
Article requires subscription to view full text
The Pharma Letter – View full story
The Herald Scotland – View full story
Drug Discovery World – View full story
PharmaShots – View full story
Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion of the collaboration, as well as royalties on […]
Amphista and Merck will collaborate to leverage Amphista’s proprietary Eclipsys™ TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million*) in combined upfront and R&D funding payments for an initial three programs Amphista will potentially receive up to €893.5 million ($1.0 billion*) in total payments […]
American Pharmaceutical Review – View full story
Bio-dundee – View full story